News Teva's Cinqaero to challenge Nucala after clearing NICE Discount swings NICE decision, drug will compete with GSK rival
News EU authorities accuse Teva of breaking competition rules Teva accused of "pay for delay" deal with Cephalon.
News AZ CEO set to take charge at Teva - report Report raises concerns about outcome of MYSTIC trial.
News Chinese trial backs base-editing drug for thalassaemia A landmark study in China has shown that a base-editing therapy developed by CorrectSequence achieved stellar results in beta-thalassaemia.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
